Synaptogenix Inc (SNPX)

[InTheTrenches]

If we have positive results in Phase 2b, then we're in an enviable position. We will have a drug that works in one disease, and the mechanism of action and preclinical results suggest that it will work in multiple diseases. Neurotrope is looking at a lot of blue sky, blu:

- Moderate-to-severe Alzheimer's
- Mild-to-moderate Alzheimer's
- Fragile-X syndrome
- Rhett's syndrome
- Traumatic brain injury
- Stroke

I haven't bothered to look at the addressable market in each of the above diseases, but I imagine the total is several billion $.

You're $10 prediction is ridiculously low, if we have positive results.

Oh, and I forgot to mention no competition for years, and an FDA that wants to get drugs quickly to market that successfully treat Alzheimer's.